The United Kingdom and the United States have finalized a landmark trade agreement that will maintain zero import taxes on UK drug products entering the American market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to increase funding on drugs through the National Health Service (NHS). This pledge guarantees that tariffs on these crucial goods will remain at zero for a duration of three years.
This deal comes after previous threats to significantly raise import taxes on branded drug products, with increases floated up to double the cost.
"This agreement with the United Kingdom strengthens the worldwide climate for innovative medicines and brings much-needed fairness to American-British pharmaceutical trade," a release said.
Commercial Significance
Drugs represent one of the UK's biggest export categories to the US, which is clearly the largest buyer for large companies like GSK and AstraZeneca.
Export figures show that in the one-year period to the end of last September, the UK exported medicines worth over eleven billion pounds to the US. This amount represented a significant portion of all goods exports in that timeframe.
"This deal secures work, stimulates capital expenditure and sets the stage for the UK to emerge as a global hub for medical research," a government official commented.
Detailed NHS Changes
The pact entails several key changes from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it deems new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to raise total NHS spending on medicines from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The sum manufacturers must refund to the NHS to control costs will be restricted at 15%. In the past, repayments were more than twenty percent.
Broader Context
This agreement follows a protracted tension between the pharmaceutical industry and the ministers over drug pricing and approval rates.
This friction were intensified by arguments that American consumers were paying significantly more for the same drugs than consumers in the other developed nations.
Recently, several large pharmaceutical investments in the UK have been halted or scrapped, while multi-billion-dollar investments have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS needed to spend more on drugs, noting that its expenditure on drugs had decreased as a share of its overall budget over the last ten years.
